Baltimore—Results from the Amblyopia Treatment Study 3 (ATS3) support offering amblyopia treatment to children aged 7 to 12 years and considering it as well for children aged as many as 17 years who have not been treated previously, reported Michael X. Repka, MD, at the Current Concepts in Ophthalmology meeting here.
Las Vegas—Identification and pretreatment of allergy patients can improve refractive surgical outcomes, said Deepinder K. Dhaliwal, MD, at a continuing medical education symposium at the American Academy of Ophthalmology annual meeting. About 20% to 30% of refractive surgery patients have associated allergies, she added.
Irvine, CA—Allergan will donate $1 million over 2 years to academic medical institutions to support fellows researching glaucoma and corneal and retinal diseases.
Las Vegas—Intracameral injection of the anti-VEGF antibody bevacizumab (Avastin, Genentech) dramatically resolves iris neovascularization and reverses neovascular glaucoma, according to the findings of a retrospective study presented here at the annual meeting of the American Academy of Ophthalmology.
New York—In a controlled trial, endocyclophotocoagulation (ECP) combined with phacoemulsification showed significant benefits in treating cataract patients who also have glaucoma, according to Stanley J. Berke, MD.
Louisville, KY—Monotherapy with latano-prost (Xalatan, Pfizer) provides more days of controlled IOP compared with bimatoprost (Lumigan, Allergan) and travoprost (Travatan, Alcon Laboratories) in patients undergoing treatment for primary open-angle glaucoma (POAG), according to Thom J. Zimmerman, MD, PhD, and colleagues.
Indianapolis—Bimatoprost (Lumigan, Allergan) seems to lower IOP more effectively in patients with glaucoma and ocular hypertension compared with travoprost (Travatan, Alcon Laboratories), according to Louis B. Cantor, MD, lead author of the study. The authors published their results in the British Journal of Ophthalmology (2006; 90:1370-1373).
Baltimore—Beta blockers continue to play an important role as an ocular hypotensive agent for both primary and adjunctive treatment, and when a beta blocker is indicated, the novel formulation of timolol maleate 0.5% ophthalmic solution with potassium sorbate (Istalol, ISTA Pharmaceuticals) is a good choice, said Alan L. Robin, MD.
Washington, DC—The FDA has issued an approvable letter for brimonidine tartrate/timolol maleate ophthalmic solution (Combigan, Allergan Inc.), outlining the remaining conditions that the company must meet to obtain final marketing approval from the agency.